Visit COVID-19 resources

[Skip to Content]

OTG response to the Shape of Training Review

Apr 29
2014

The Ophthalmic Trainees’ Group has issued its response to the Shape of Training review. OTG_response_to_the_Shape_of_Training_review

  • 29 April 2014

Quality Standards for Services for Patients with Learning Disabilities

Apr 17
2014

There are numerous personal accounts nationwide of ways in which ophthalmologists have been able to enhance the quality of life of people with learning disability. The impact of an intervention to improve sight should not be underestimated. In 2011 The Royal College of Ophthalmologists, with the support of SeeAbility, VISION 2020 UK and the RNIB,

  • 17 April 2014

Safeguarding children and young people: roles and competences for health care staff

Apr 07
2014

All health staff must have the competences to recognise child maltreatment and to take effective action as appropriate to their role. They must also clearly understand their responsibilities, and should be supported by their employing organisation to fulfil their duties. Chief Executive officers and independent contractors such as GPs, in particular have a responsibility to

  • 7 April 2014

Response to Mr Michael Clarke’s personal views ‘NHS sight tests include unevaluated screening examinations’

Mar 19
2014

College Statement The Royal College of Ophthalmologists Issues a Response to Mr Michael Clarke’s personal views expressed in his paper titled ‘NHS sight tests include unevaluated screening examinations that lead to waste’. In a personal view recently published on bmj.com, a leading eye doctor says that opticians are making too many referrals to doctors. Mr

  • 19 March 2014

Choice of anti VEGF agents for wet AMD treatments

Mar 07
2014

College Statement Ophthalmologists have a choice of two anti-VEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). Photodynamic therapy is also licensed and approved and still has a role in a small subset of patients.  An anti-VEGF agent is generally used for the treatment of wet AMD

  • 7 March 2014